TREACE MEDICAL CONCEPTS, INC. (TMCI): Price and Financial Metrics
TMCI Price/Volume Stats
Current price | $12.00 | 52-week high | $27.97 |
Prev. close | $11.88 | 52-week low | $5.27 |
Day low | $11.60 | Volume | 491,600 |
Day high | $12.30 | Avg. volume | 543,162 |
50-day MA | $13.58 | Dividend yield | N/A |
200-day MA | $15.20 | Market Cap | 741.06M |
TMCI Stock Price Chart Interactive Chart >
TMCI POWR Grades
- Sentiment is the dimension where TMCI ranks best; there it ranks ahead of 50.49% of US stocks.
- TMCI's strongest trending metric is Stability; it's been moving down over the last 26 weeks.
- TMCI's current lowest rank is in the Stability metric (where it is better than 4.66% of US stocks).
TMCI Stock Summary
- TREACE MEDICAL CONCEPTS INC's stock had its IPO on April 23, 2021, making it an older stock than just 7.67% of US equities in our set.
- Revenue growth over the past 12 months for TREACE MEDICAL CONCEPTS INC comes in at 39.17%, a number that bests 88.33% of the US stocks we're tracking.
- In terms of volatility of its share price, TMCI is more volatile than 90.07% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to TREACE MEDICAL CONCEPTS INC, a group of peers worth examining would be AVNS, CDXC, NEO, AMRN, and AQB.
- TMCI's SEC filings can be seen here. And to visit TREACE MEDICAL CONCEPTS INC's official web site, go to www.treace.com.
TMCI Valuation Summary
- TMCI's price/earnings ratio is -16.5; this is 156.6% lower than that of the median Healthcare stock.
- Over the past 33 months, TMCI's price/earnings ratio has gone up 282.5.
Below are key valuation metrics over time for TMCI.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
TMCI | 2023-12-29 | 4.5 | 5.7 | -16.5 | -20.0 |
TMCI | 2023-12-28 | 4.5 | 5.8 | -16.7 | -20.2 |
TMCI | 2023-12-27 | 4.5 | 5.8 | -16.6 | -20.1 |
TMCI | 2023-12-26 | 4.5 | 5.7 | -16.4 | -19.9 |
TMCI | 2023-12-22 | 4.3 | 5.4 | -15.7 | -19.1 |
TMCI | 2023-12-21 | 4.2 | 5.3 | -15.4 | -18.7 |
TMCI Price Target
For more insight on analysts targets of TMCI, see our TMCI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $35.00 | Average Broker Recommendation | 1.38 (Strong Buy) |
TREACE MEDICAL CONCEPTS, INC. (TMCI) Company Bio
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.
Latest TMCI News From Around the Web
Below are the latest news stories about TREACE MEDICAL CONCEPTS INC that investors may wish to consider to help them evaluate TMCI as an investment opportunity.
Treace to Present at 42nd Annual J.P. Morgan Healthcare ConferenceTuesday, January 9, 2024, at 3:45 pm Pacific TimePONTE VEDRA, Fla., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on T |
Does the New Anti-Obesity Medicine Affect Treace Medical Concepts (TMCI)?TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter investor letter. A copy of the same can be downloaded here. In the quarter the fund returned -3.67% (net), compared to -7.32% return for the Russell 2000 Growth Index. Year-to-date the fund returned 11.56% (net) compared to 9.59% return for […] |
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q3 2023 Earnings Call TranscriptTreace Medical Concepts, Inc. (NASDAQ:TMCI) Q3 2023 Earnings Call Transcript November 11, 2023 Operator: Good day and thank you for standing by. Welcome to Treace Medical Concepts Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to turn the conference over to your […] |
Q3 2023 Treace Medical Concepts Inc Earnings CallQ3 2023 Treace Medical Concepts Inc Earnings Call |
Treace Medical Concepts Reports Third Quarter 2023 Financial ResultsPONTE VEDRA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights: Revenue of $40.8 million in the third quarter, a 23% increase over same period last ye |
TMCI Price Returns
1-mo | -22.68% |
3-mo | 9.29% |
6-mo | -10.65% |
1-year | -49.00% |
3-year | N/A |
5-year | N/A |
YTD | -5.88% |
2023 | -44.54% |
2022 | 23.34% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...